# Lilly sets up next-gen obesity battle with full phase 3 retatrutide data

> **Newsylist Open Intelligence Dossier** · First detected: 2026-09-30 15:29 UTC · Category: Business · Sources: 3 · Current Velocity: 1.3

## Key People, Organizations & Locations
Lilly

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| Yahoo | EASD 2026: Lilly’s amylin-tirzepatide combo beats its weight loss drug alone | 2026-09-30 07:06 | [Source Link](https://news.google.com/rss/articles/CBMimAFBVV95cUxPUjVNcmUtZV9kRkFNM2FVdjYtdlFwRXBNaTVTX3h5QlFBRTR0RVYwT2ZCUjZyMEZtVGRZMlNxMG13MVpTYlQtZ1ktZF9lN0JyeG93dGo0Yl9HellZejBoRUkxNmQzTGc2OFdnWUptRmJFT0FkVXhUdS11TnNNZm42dXBhbXViNUhRZDVDSl9YNHE1WjkxZzZ2Sg?oc=5) |
| Eli Lilly | Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes | 2026-09-30 07:06 | [Source Link](https://news.google.com/rss/articles/CBMiugFBVV95cUxNallJaHFhQkZPLVlVUnRBLWtpNkJNTzlrY3hPbWFYYW9kYW05U2UxNmliT2hqWmk4NUloRVh5b1cxLXh3aGoyQ0JkNVQzYndqcF84dDd0U0k3ZHJnUUVsS2ZJenUzVGJfemt6TS1oc2VBckYwNEFIZWE1MG5xdmVGQVI3VU5STVFjbWlZYU1BV3FzQjNYVVdGd1d5T09XUm1ydGlVeTdmQjlHSEJxMWF5VndUalNNWi04ZWc?oc=5) |
| Bloomberg.com | Lilly Drug Combo Spurs Record Weight Loss in Diabetes Study | 2026-09-30 07:06 | [Source Link](https://news.google.com/rss/articles/CBMirwFBVV95cUxNa3FfSjNvTTZrVzFKZGpBemY3czdpb2NwcWVwdldDdUc1SUhjZktKcURpYXlUNmhNY3RZNVkzUDRzUTh5VkttYVpWa3JQdDJnNEtMMnlFc1l4R1prVEJBelF1dWhDQ3R6bDhpVkxrTl9KbEY2TWNqdWtrM0UweDFRT0hnYkdhNi10M3JidlROaFZtYUJpY3ZVVVpjN1FLMHM5dFhzU0pXcV9Wc3RuYWpF?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-09-30/lilly-sets-up-next-gen-obesity-battle-with-full-phase-3-retatrutide-data*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*